EUVIMEDEUVIMED entdecken
Crossref

FABP4 Inhibitor Alleviates Lipopolysaccharide-Induced HUVEC Injury by Inactivating NF-κB and Activating PPARγ

Shan Sun, Xiaoyu Duan, Qinqin Wu, Xiaofen Bu, Yingxia He, Xiaoyan Ming, Hong Zhu

International Heart Journal · 2024

DOI: 10.1536/ihj.24-272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Heart Journal, 2024. Verfasst von Shan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology. Hauptthemen laut MEDLINE: Human Umbilical Vein Endothelial Cells, Lipopolysaccharides, Fatty Acid-Binding Proteins, PPAR gamma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study aims to examine the effect of FABP4 on inflammatory response and angiogenesis in the cell model of atherosclerosis and to explore its potential mechanism.Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting, the mRNA and protein levels of FABP4 in human umbilical vein endothelial cells (HUVECs) treated with lipopolysaccharide (LPS) or oxidized low-density lipoprotein for 6, 12, 24, or 48 hours were measured. To silence FABP4 expression and NF-κB signaling in HUVECs, FABP4 inhibitor and NF-κB inhibitor were utilized. To assess cell survival rate and apoptosis, methyl thiazolyl tetrazolium assays and flow cytometry analysis were conducted. Genes related to cholesterol metabolism, including LOX-1, ABCA1, and ABCG1, were subjected to RT-qPCR and western blotting. Moreover, protein levels of apoptotic markers (Bcl-2 and Bax), PPARγ, the phosphorylated levels of NF-κB p65, and angiogenetic markers (ICAM1, VCAM1, and VEGF) were quantified via western blotting. Using an enzyme-linked immunosorbent assay, concentrations of inflammatory cytokines in HUVECs were measured.FABP4 expression was upregulated in LPS-stimulated HUVECs. The silencing of FABP4 lowered LOX-1 and p65 levels while upregulating ABCA1 and ABCG1 expression in the context of LPS. Furthermore, the inhibition of FABP4 or NF-κB signaling promoted the growth of HUVECs, upregulated Bcl-2 and PPARγ protein levels, and reduced Bax levels, angiogenetic markers, and inflammatory cytokines in the context of LPS. The combination of FABP4 inhibitor and NF-κB inhibitor treatment amplified the above-mentioned effects on cell growth, angiogenesis, and inflammation.Inhibition of FABP4 reduces LPS-induced HUVEC cell damage via the inactivation of NF-κB p65 and activation of PPARγ signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Umbilical Vein Endothelial CellsLipopolysaccharidesFatty Acid-Binding ProteinsPPAR gammaNF-kappa BApoptosisHumansSignal TransductionAtherosclerosisCells, CulturedCell SurvivalLipoproteins, LDL

Stichwörter der Autor:innen

AngiogenesisApoptosisAtherosclerosisEndothelial dysfunctionInflammation

Substanzen

LipopolysaccharidesFatty Acid-Binding ProteinsPPAR gammaFABP4 protein, humanNF-kappa Boxidized low density lipoproteinLipoproteins, LDL

Autor:innen und Institutionen

  • Department of General Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology.

Zitieren

APA

Sun, S., Duan, X., Wu, Q., Bu, X., He, Y., Ming, X., & Zhu, H. (2024). FABP4 Inhibitor Alleviates Lipopolysaccharide-Induced HUVEC Injury by Inactivating NF-κB and Activating PPARγ. International Heart Journal. https://doi.org/10.1536/ihj.24-272

Vancouver

Sun S, Duan X, Wu Q, Bu X, He Y, Ming X, et al. FABP4 Inhibitor Alleviates Lipopolysaccharide-Induced HUVEC Injury by Inactivating NF-κB and Activating PPARγ. International Heart Journal. 2024. doi:10.1536/ihj.24-272

BibTeX
@article{Sun2024,
  author = {Sun, Shan and Duan, Xiaoyu and Wu, Qinqin and Bu, Xiaofen and He, Yingxia and Ming, Xiaoyan and Zhu, Hong},
  title = {FABP4 Inhibitor Alleviates Lipopolysaccharide-Induced HUVEC Injury by Inactivating NF-κB and Activating PPARγ},
  journal = {International Heart Journal},
  year = {2024},
  doi = {10.1536/ihj.24-272}
}
Kostenlos starten →